BRAINMAX PROMOMED 250mg + 250mg 40 capsules

BRAINMAX® is an antioxidant and metabolic agent.

MELDONIUM (trimethylhydrazinium propionate) is a structural analogue of the precursor of carnitine-gamma-butyrobetaine, a substance that is found in every cell of the human body.
Trimethylhydrazinium propionate under conditions of ischemia restores the balance of oxygen delivery and consumption in cells, prevents disruption of adenosine triphosphate (ATP) transport; At the same time, it activates glycolysis, which occurs without additional oxygen consumption.
Ethylmethylhydroxypyridine succinate, by blocking the process of lipid peroxidation, reduces the number of free radicals, improves the structure and function of the cell membrane, the transport of neurotransmitters and signal transmission in synapses.
The use of a complex of trimethylhydrazinium propionate and ethylmethylhydroxypyridine succinate leads to a synergistic pharmacodynamic interaction of the two components in the form of conformation-selective agonism to receptors, which increases the neuroprotective activity of the preparation . Under conditions of hypoxia, the preparation BRAINMAX® leads to activation of energy production in mitochondria, and under conditions of decreased blood supply, it helps to preserve the structure and vital activity of cells, in particular neurons and cardiomyocytes.
When using the preparation BRAINMAX®, the antioxidant, antihypoxic, membrane- and stress-protective, anticonvulsant, anxiolytic, nootropic and anti-ischemic effect of two active substances exceeds the pharmacological effect of each of the components used separately, which leads to a decrease in the clinical manifestations of cerebrovascular insufficiency, an increase in the level of patient mobility, improved cognitive functions, improved memory and attention, normalized emotional state, reduced symptoms of mental and physical stress, increased performance, increased tolerance to mental and physical stress, improved blood supply to organs and tissues, cardioprotective effects and improved neurological status.
In conditions of ischemia, the preparation BRAINMAX® slows down the formation of a necrotic zone and damage to myocardial cells, reduces platelet aggregation, helps accelerate rehabilitation after cardiovascular events, supports the energy metabolism of the heart, which increases tolerance to physical exercise and helps reduce the frequency of angina attacks in heart failure. It has a lipid-lowering effect, reduces the content of total cholesterol and low-density lipoproteins. Promotes detoxification and improves the condition of the nervous system during alcoholism and withdrawal syndrome.
A clinical placebo-controlled study demonstrated the effectiveness of BRAINMAX® for the treatment of patients with post-Covid asthenic syndrome and symptoms characteristic of conditions after a viral infection, such as asthenia, sleep disturbances, headaches, dizziness, chronic fatigue syndrome, cognitive impairment, feeling of anxiety.

Indications:

• As part of complex therapy for cerebral circulatory failure.
• Mild cognitive impairment, accompanied by such manifestations as memory impairment, absent-mindedness, decreased ability to concentrate and learn, and difficulties in learning new information.
• Reduced performance.
• Mental and physical overload.
• Asthenic conditions, including after a new coronavirus infection, accompanied by such manifestations as increased fatigue, sleep disturbances, headaches, dizziness, emotional lability, and cognitive impairment.

Directions for use and dosage:

The preparation BRAINMAX® is prescribed orally.

For complex therapy of cerebral circulatory failure, BRAINMAX® is taken 2 capsules (500 mg + 500 mg) 1 time per day. The course of treatment is 4 weeks. The daily dose can be increased to 2 capsules (500 mg + 500 mg) 2 times a day according to the decision of the attending physician. The duration of treatment can be increased according to the decision of the attending physician.

For mild cognitive impairment, decreased performance, asthenic conditions, mental and physical overload, the daily dose of BRAINMAX® for adults is 2 capsules (500 mg + 500 mg). The daily dose is taken in one dose (2 capsules in the morning), or divided into 2 doses (1 capsule 2 times a day). The course of treatment is 10-14 days.

For asthenic conditions after a new coronavirus infection, the daily dose of BRAINMAX® for adults is 4 capsules (1000 mg + 1000 mg). The preparation BRAINMAX® is taken 2 capsules (500 mg + 500 mg) 2 times a day. The course of treatment is 30 days.
Due to the possible development of an stimulating effect, BRAINMAX® is recommended to be taken in the first half of the day.

Ingredients per 1 capsule:

Active ingredients: ethylmethylhydroxypyridine succinate - 250.0 mg, meldonium dihydrate - 250.0 mg.
Excipients: corn starch - 35.7 mg, microcrystalline cellulose type 101 - 22.0 mg, macrogol 6000 - 20.0 mg, microcrystalline cellulose type 102 - 10.0 mg, colloidal silicon dioxide - 6.8 mg, magnesium stearate - 5.5 mg.
Hard gelatin capsule No. 00
Capsule body: titanium dioxide (E 171) - 2.0%, gelatin - up to 100.0%.
Capsule cap: titanium dioxide (E171) - 1.0%, indigotine dye (E132) - 0.1333%, gelatin - up to 100.0%.

Contraindications:

• hypersensitivity to the components of the preparation ;
• acute liver failure;
• acute renal failure;
• increased intracranial pressure (in case of impaired venous outflow and intracranial tumors);
• pregnancy;
• lactation period;
• children under 18 years of age.

Carefully:

Chronic liver and kidney diseases, bronchial asthma
Use during pregnancy and breastfeeding
The preparation BRAINMAX® is contraindicated during pregnancy and breastfeeding due to insufficient data on the effectiveness and safety of the preparation during these periods. Breastfeeding should be discontinued before starting the preparation .

Special instructions:

Meldonium may give a positive result during doping control. Since January 1, 2016, meldonium has been included in the list of prohibited substances of the World Anti-Doping Agency.
Patients with chronic liver and kidney diseases should be careful with long-term use of the preparation .
There is insufficient data on the use of the preparation in children under 18 years of age.
If the condition does not improve or worsens after a course of therapy, you should consult a doctor. If you need to take the preparation for a long time (more than a month), it is recommended to consult a specialist.
Impact on the ability to drive vehicles and machinery
During the period of taking the preparation , care should be taken when performing work that requires increased concentration and speed of psychomotor reactions (driving vehicles, machinery, etc.).

Packaging and release form:

Capsules, 250 mg + 250 mg - 40 pcs with instructions for medical use in a pack.

Preparation interactions:

MELDONIUM

Enhances the effect of coronary dilation agents of some antihypertensive preparation s of cardiac glycosides. Can be combined with prolonged forms of nitrates, other antianginal preparation s, anticoagulants, antiplatelet agents, antiarrhythmic preparation s, diuretics, bronchodilators.
Due to the possible development of tachycardia and arterial hypotension, caution should be exercised when combined with nitroglycerin (for sublingual use) and antihypertensive preparation s (especially alpha-blockers and short-acting forms of nifedipine).
Concomitant use of the preparation with other preparation s containing meldonium is not allowed, as the risk of adverse reactions may increase.

ETHYLMETHYLHYDROXYPYRIDINE SUCCINATE

Ethylmethylhydroxypyridine succinate is combined with all preparation s used to treat somatic diseases.
Enhances the effect of benzodiazepine preparation s, antidepressants, anxiolytics, antiepileptic preparation s (carbamazepine) and antiparkinsonian preparation s (levodopa), nitrates. Reduces the toxic effect of ethanol.

Effect:

MELDONIUM

After oral administration, meldonium is rapidly absorbed from the gastrointestinal tract. Bioavailability - 78%. The time to reach maximum concentration in blood plasma is achieved 1-2 hours after oral administration. Metabolized mainly in the liver with the formation of two main metabolites, which are excreted by the kidneys. The half-life (T1/2) when taken orally depends on the dose and is 3-6 hours. Trace concentrations of the preparation remain in the body for a long time.

ETHYLMETHYLHYDROXYPYRIDINE SUCCINATE

Rapidly absorbed when taken orally. The maximum concentration (Cmax) at doses of 400-500 mg is 3.5-4.0 mcg/ml. Quickly distributed in organs and tissues. The average retention time (MRT) of the preparation in the body when taken orally is 4.9-5.2 hours. Metabolized in the liver by glucuron conjugation. 5 metabolites have been identified: 3-hydroxypyridine phosphate is formed in the liver, with the participation of alkaline phosphatase, it breaks down into phosphoric acid and 3-hydroxypyridine; The 2nd metabolite is pharmacologically active, is formed in large quantities and is found in the urine for 1-2 days. after administration; 3rd - excreted in large quantities in the urine; 4th and 5th - glucuron conjugates. The half-life (T1/2) when taken orally is 2.0-2.6 hours. It is rapidly excreted in the urine, mainly in the form of metabolites and in small quantities unchanged. The most intensive elimination occurs during the first 4 hours after taking the preparation . Rates of urinary excretion of unchanged preparation and metabolites have individual variability.

Overdose:

The preparation is low-toxic and does not cause severe adverse reactions.
Symptoms: decreased blood pressure, accompanied by headache, tachycardia, dizziness and general weakness. Drowsiness, insomnia.
Treatment: treatment, as a rule, is not required - the symptoms disappear on their own within 24 hours. In case of severe manifestations, supportive and symptomatic treatment is carried out.

Storage temperature: 2℃ to 25℃

Guaranteed authenticity and quality:

100% Original from PROMOMED (Russian Federation)

Promomed Group of Companies is one of the leaders in the Russian pharmaceutical industry, an active participant in the country’s national preparation safety system. We specialize in the development, production and promotion of preparation s used in such areas of medicine as infection control (antiviral and antibiotics), endocrinology, neurology, oncology, and general therapy. The company is one of the Russian leaders in the production of preparation s for the treatment of COVID-19 and a leader in the segment of production of preparation s for weight management. The company's product portfolio includes more than 250 preparation s, 80% of which are included in the list of vital and essential preparation s (VED). Over 100 new preparation s are at various stages of development and registration. The complex of research laboratories for the development of new preparation s and finished dosage forms of the Promomed Group of Companies occupies 2,000 sq.m.

Development and production:

PROMOMED BIOCHIMIK (Russian Federation)